News Releases

Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Synlogic to Present at the Jefferies Global Healthcare Conference

Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria

Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

Synlogic Provides Corporate Update and Outlook for 2023

Synlogic Therapeutics